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a negative PET scan is about 5%. Combined with a realistic sensitivity 
of mediastinoscopy of about 85%, we predicted that 25 patients need 
to undergo invasive staging in order to identify a single patient with N2 
disease. In a sensitivity analysis (dropping PET sensitivity and speciﬁc-
ity for this subset to 0.85 and 0.70, respectively), we found that these 
data are robust With nodes >15mm short axis diameter, the post-test 
probability of N2 disease is 0.21, suggesting that invasive evaluation 
is indicated in patients with such nodes at CT without positive 18FDG 
signal. Since 18FDG is not a tumor-speciﬁc agent, clinically decisive 
PET-positive lesions need to be conﬁrmed except in cases of widely 
disseminated extrathoracic tumor spread.
PET reading
Visual detection of ‘hot spots’ is the mainstay of mediastinal PET read-
ings. PET allows for very accurate signal quantiﬁcation. In the clinical 
setting, one uses the standardized uptake value (SUV), which basically 
is the ratio of measured activity in the tumor and the injected 18FDG 
dose. Because SUV can be readily obtained from whole body scans, it 
is the most widely applied method. The aim of adding quantiﬁcation 
to PET reading systems would be to improve speciﬁcity and perhaps 
reduce observer variation. Even though there is some evidence to sup-
port this notion [5] there is no generally accepted SUV cut-off (and due 
to the abovementioned partial volume effects it is unlikely that there is 
one). Since prevailing PET methods are heterogeneous meta-analysis 
is impossible. Several initiatives are underway to promote interinstitute 
calibration and standardization [6,7]. Functional imaging with PET 
involves biology and physics, and as such clearly puts higher demands 
on its users than we were used to in anatomical imaging: in order to 
obtain generally applicable data (e.g. SUV numbers) the full trajectory 
of patient preparation, image acquisition -, - reconstruction procedures 
and data-analysis need to be covered, and this is not trivial. Alterna-
tively, use of PET-CT rather than visual co reading of PET and CT adds 
speciﬁcity by identifying aspeciﬁc non-nodal uptake. 
Requirements for rational use of mediastinal PET readings 
1. the primary tumor needs to be 18FDG avid, since PET-detection of 
malignant tissue depends on contrast between uptake in target vs. back-
ground. Broncho-alveolar cancer cells can lack GLUT-1 transporters 
rendering the PET signal negative. On average, squamous cell cancer 
tends to have somewhat higher 18FDG uptake than adenocarcinoma, 
but in meta-analyses no clear difference in PET accuracy was reported. 
Assessment of a lower level 18FDG avidity relies upon the nuclear 
medicine physician’s judgment rather than upon a speciﬁed level of 
avidity (SUV) - for the same reasons as outlined before. Fortunately, 
this visual assessment has a low observer variation [8]. Therefore, with 
high clinicopathological suspicion of NSCLC but low 18FDG uptake in 
the primary process, a negative mediastinal reading should not guide 
clinical management. 
2. nodal stations directly adjacent to the primary tumor are likely not to 
be recognized at PET but remain hidden in the activity of the primary 
tumor. Note that most PET acquisitions are obtained during shallow 
breathing, unlike diagnostic CT scans; fusion of low-dose CT scans 
and PET (as customary with PET-CT) accounts for the potential effect 
of tumor shift during deep inspiration. The nuclear medicine physician 
should report which stations are subject to this potential problem.
3.similarly, spatial resolution limitations reduce anatomical conﬁdence 
of PET readings when trying to separate N1 and adjacent N2 stations. 
PET(-CT) and restaging
Several studies have investigated the diagnostic accuracy of PET to 
restage the mediastinum after induction therapy for locally advanced 
NSCLC. The results are clearly more heterogeneous than in the upfront 
staging situation. Among the potential effect modiﬁers one needs 
to consider the included patient spectra, the quality of the reference 
test (gold standard), type of induction therapy (chemo- and/or radio-
therapy), timing of PET vs. the intervention, PET vs. PET-CT, and PET 
classiﬁcation systems and - interpretation criteria. Obviously, once the 
diagnostic accuracy of PET to provide mediastinal mapping is clariﬁed, 
these data need to be ﬁtted into diagnostic and management algorithms. 
Preferably, research in either domain should be ‘in sync’ to prevent that 
diagnostic procedures keep pace with therapeutic developments. With 
the transition from induction chemotherapy to chemoradiation, this was 
clearly not the case. The standardization momentum in the PET com-
munity may be an important vehicle to allow for such joint efforts. 
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Lung cancer more commonly spreads to the mediastinum than to other 
anatomic sites requiring thorough evaluation of the mediastinum in 
cases where there is no other evidence of metastases. The decision to 
treat for multimodality therapy hinges on the. An unanswered question 
is whether pre- versus post-operative chemotherapy provides better 
survival. Though, preoperative treatment allows for higher chemothera-
peutic drug delivery and more delivery to the loco-regional area of the 
primary tumor. By identifying those patients less likely to beneﬁt from 
surgical resection, such as contralateral and/or multinodal station/gross 
tumor involvement, unnecessary or “futile” thoracotomies should be 
minimized. Previously estimated to be as high as 30-40% now appear 
to be in the 5 to 10% range given the availability of high-resolution 
computed and positron emission tomographies (CT, PET, PET/CT) and 
even lower with a thoroughly pathologically-staged mediastinum. To 
highlight the importance of mediastinal lung cancer involvement, the 
American Joint Committee for Cancer Staging and Results Reporting 
and the American Thoracic Society adopted the Naruke staging map 
by provide systematic information on the prognosis of lung cancer 
patients. , Each region is numbered in the mediastinum and hilar, as it 
relates to the trachea, the main stem bronchi and the great vessels. The 
goals of mediastinoscopy are to better understand the biology of the 
patient’s disease. It allows selection of those patients who are at risk 
for earlier recurrence and poorer lung cancer survival and reduces the 
likelihood for a futile thoracotomy.
Mediastinoscopy is the “gold standard” method for assessing lung 
cancer mediastinal involvement and provides a minimally-invasive 
means of evaluating the mediastinal lymph nodes for the presence and 
degree of metastatic involvement, including microscopic, gross and 
trans-capsular involvement and “matted” of nodes; as well as direct 
extension of the primary tumor into the mediastinal pleura and into 
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central thoracic structures. Though, mediastinoscopy is not equivalent 
in all hands. Little and colleagues reported on the American College 
of Surgeons’ survey of 729 hospitals and 40,090 patients, and found 
that a paltry 27.1% underwent preoperative mediastinoscopy with only 
46.6% having nodal tissue taken in the specimen. A signiﬁcant percent-
age of the remainder had only one node sampled. Furthermore, 42% of 
those resected had no mediastinal staging either by mediastinoscopy or 
thoracotomy. This is strong evidence that the vast majority of medias-
tinoscopies performed in United States are inadequate for staging lung 
cancer. There is a great deal of variability in surgical training, experi-
ence and skill level, as well as signiﬁcant differences among pathology 
programs, pathologists, and patient characteristics and equipment fac-
tors that allow for the minimum of 3 main nodal stations to sufﬁciently 
stage the mediastinum: the subcarina (level 7), right (level 4R) and left 
paratracheal nodes (level 4L).
The history of mediastinoscopy coincidentally developed along with 
the development of the surgical treatment of lung cancer. In 1949, to 
minimize futile thoracotomies, Daniels recommended the use of the 
scalene node biopsy. It was infrequently positive for disease and mini-
mally impacted on the frequency of unnecessary thoracotomies. In-
stead, Harken proposed the use of cervical mediastinoscopy (CM) and 
ﬁrst reported its use in a series of patients in 1954. The procedure was 
performed using a Jackson laryngoscope and by some a vaginal specu-
lum. As reported in 1959, Carlens enhanced the technique by develop-
ing the Carlens mediastinoscope, allowing greater control during the 
dissection and a smaller incision. Now, there are numerous variations 
on the basic model described. CM allows for evaluation of lymph node 
stations 2R, 2L, 3 anterior, 4R, 4L, 7 and in experienced hands 10R, 
10L and 11R. Both sampling and nodal dissection can be performed 
through the scope. In 1968, McNeill and Chamberlain introduced the 
staging technique to assess the anterior mediastinum, the Chamberlain 
mediastinotomy. The anterior mediastinotomy and more often used the 
anterior mediastinoscopy provides access to levels 5 and 6. Then, in 
1974, Ginsberg reported the use of the extended mediastinoscopy to 
perform an aorto-pulmonary window (AP) mediastinal nodal biopsy/
resection through the same cervical incision used to perform the cervi-
cal mediastinoscopy. In 2004, Zielinski introduced the transcervical 
extended mediastinal lymphadenectomy or TEMLA as a transcervi-
cal means to completely remove all nodes from stations 1, 2R, 2L, 3 
anterior, 4R, 4L, 5, 6, 7, 8R and 8L; and felt to have greater staging 
sensitivity and potentially curative. A prospective randomized analysis 
was performed comparing TEMLA to CM in 41 patients and found that 
the complications were not signiﬁcantly different, the pain was greater 
with TEMLA, the time for the procedure was 2-3 hours versus 1 hour 
and the sensitivity and negative predictive value for TEMLA was 2- to 
3-fold superior to CM. 
CM and anterior mediastinotomy are performed under general anesthe-
sia. For CM the patient is positioned supinely with the head and neck 
hyperextended. A 3-4 cm transverse incision is made in the midline 
above approximately 1-2 cm above the level of the suprasternal notch. 
The dissection is continued to beneath the fascia where a plane is raised 
between the trachea and the fascia. After a digital exploration, the medi-
astinoscope is passed. Mediastinal nodes are teased away from mediasti-
nal structures. Node sampling or complete resection is then performed. 
To evaluate potential metastatic involvement of the AP window lymph 
nodes, the anterior mediastinotomy is performed in the left parasternal 
area. A 5- to 6-cm transverse incision immediately parasternally and the 
second or the third costal cartilage is resected. Using sharp and blunt 
dissection extrapleural exposure of the AP window is obtained and 
the lymph nodes there can be either sampled or completely resected. 
Because of the potential postoperative discomfort that can occur either 
from the surgical incision/resection or from the anterolateral chest wall 
instability, costochondral resection has been supplanted by the intercos-
tal entry of the mediastinoscope. Others have found greater utility in 
performing thoracoscopy rather than mediastinotomy or mediastinos-
copy for the purpose of staging the AP window. A rightward parasternal 
approach can also be performed for evaluating suspicious right-sided, 
pre-vascular anterior mediastinal or hilar lymph nodes. 
The Ginsberg extended mediastinoscopy is performed through the same 
cervical incision as the CM to approach the AP window lymph nodes, 
stations 5 and 6, by incising the fascia medial to the origin of the left 
common carotid and dissecting anterior to the arch of the aorta and poste-
rior to the innominate vein. The mediastinoscope places downward trac-
tion on the arch of the aorta to gain exposure to the AP window nodes. 
TEMLA is performed through a 5- to 7-cm suprasternal transverse inci-
sion where the strap muscles are divided and the superior mediastinum 
and associated neural and vascular structures are exposed. A complete 
mediastinal extirpation of lymphatic tissue is performed in a systematic 
fashion. An anterior sternal retractor is used to provide greater exposure 
as well as a mediastinoscope and thoracoscope as necessary to gain 
visualization.
The advantages of CM include that it allows for bilateral evaluation of 
the mediastinum through the same incision. It is quick, simple and safe. 
It reduces futile thoracotomies to fewer than 5%. It provides a sampling 
error less than ﬁne needle aspiration (FNA). Using the information on 
CT and PET signiﬁcantly reduces the error involved in mediastinos-
copy. It provides unique information from which other tests are not ca-
pable: the number of nodes involved, the precise location of the nodes 
and their gross appearance, such as a matted appearance and transcap-
sular invasion. Unfortunately, it requires general anesthesia and a sur-
geon who has signiﬁcant experience with the procedure. The mortality 
from the procedure is 0-0.08%. Bleeding, local trauma to mediastinal 
structures such as the recurrent laryngeal nerve, the trachea and the 
esophagus, air embolism, stroke, tumor implant have all been known 
complications of the procedure. There is no access to the retrotracheal, 
para-aortic or inferior mediastinal nodes. The contraindication to its 
use is the presence of a aneurysm or dissection of the ascending aorta, 
arch and/or the inominate artery. Relative contraindications are prior 
mediastinoscopy, tracheostomy, a large goiter, prior mediastinitis and 
superior vena caval syndrome. 
For potential surgical candidates the prevalence of mediastinal lymph 
node involvement is between 35 and 45%. With the advent of the high 
resolution CT and PET technologies the role for mediastinoscopy is 
not clear. Further, with the addition of esophageal ultrasound (EUS) 
and endobronchial ultrasound (EBUS)-directed FNA, further staging of 
the mediastinum can be performed without entering the mediastinum, 
without general anesthesia or an incision and entry into the mediasti-
num. Perhaps by performing FNA, the potential for mediastinal spread 
might be reduced. Furthermore by not incising the fascial planes of the 
mediastinum, allows for later easier post-chemotherapy or post-radia-
tion mediastinoscopy and potential more precise exenteration of the 
mediastinum. Cases in which mediastinoscopy is unlikely to provide 
any additional information are in:
(1) Patients that are found to have biopsy-conﬁrmed metastatic disease 
or metastatic disease to the brain or bone, or in diagnosed lung can-
cer cases with extensive mediastinal invasion or in those cases with 
biopsy-proven bulky mediastinal adenopathy.
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(2) Patients with discrete mediastinal lymph node enlargement and 
contralateral FNA-demonstrated disease. 
FDG PET might provide information concerning the likelihood of 
involvement of the node as well as possible metastatic disease. The false 
positive rate for PET in the mediastinum is 15 to 20% and the false nega-
tive rate for patients with enlarged lymph nodes is 15 to 25%. Thus, per-
forming a needle aspiration technique either by EUS or EBUS is warrant-
ed. Given the false negative rate of 20 to 30%, ﬁnding a negative FNA 
should be followed by a mediastinoscopy. Patients with adenocarcinoma, 
large cell carcinoma or other histologies that are more likely metastatic, 
primary lesions larger than 2- 3 cm in largest dimension, centrally located 
tumors, tumors that have clinical N1 disease, those with FDG-PET SUV 
of > 7 or multiple abnormalities on PET or in those that have serum 
CEA level > 5 ng/L are all considered risk factors for potential N2 or N3 
disease and necessitate FNA and if negative, mediastinoscopy. In patients 
with peripheral primary tumors with no lymph node enlargement on CT, 
no other risk factors and no primary tumor FDG uptake (< 2.5) have a 
mediastinal disease prevalence of less than 3%.
In summary, patients who have enlarged or suspicious appearing medi-
astinal nodes on CT and/or those with FDG-PET or PET/CT uptake, an 
EUS and/or EBUS can be performed to conﬁrm the presence of disease 
rather than assuming malignant involvement. A thorough evaluation of 
the mediastinum should be performed. If metastatic disease is not found, 
then mediastinoscopy should be performed as the negative predictive 
value of FNA is insufﬁcient to rule out the presence of metastasis. If it 
is found, then induction therapy can be used. For those patients with a 
negative mediastinum on PET and CT and if the lesion is peripheral, 
in the outer third of the lung ﬁeld and the SUV of the primary is less 
than 2.5, then mediastinoscopy is unlikely to provide further helpful 
information. For more adenoscarcinomas and large cell cancers or cen-
tral or lesions larger than 4 cm or clinically N1 patients or in whom the 
SUV of the primary is larger than 7, then the prevalence of mediastinal 
involvement is higher, increasing the error of CT and PET. The negative 
predictive value in these cases is not sufﬁcient to eliminate the prob-
ability of disease in the mediastinum. Prospective trials evaluating the 
use of TEMLA should be performed to assess its ability in providing a 
survival advantage, but it does appear to provide superior staging infor-
mation. Future methods of genetic analysis of the primary tumor as well 
as genetic and marker analyses of the lymph nodes, bronchial washings, 
bone marrow and serum might provide greater prognostic information 
than simple histological examination of the mediastinal lymph nodes. If 
this is the case, mediastinoscopy might be unnecessary. 
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cancer detection
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Lung cancer is the leading cause of cancer-related death in the U.S. 
and is projected to reach epidemic levels in the world during the 21st 
century. Chemotherapy has been largely ineffective in producing 
complete responses or cures in advanced disease so that over 85% of 
patients with lung cancer eventually succumb to the disease. Mortality 
could be reduced greatly by identifying persons at high risk for cancer 
and developing effective interventions to impede or reverse respiratory 
carcinogenesis. Key to the success of this strategy is the identiﬁcation 
of highly efﬁcacious preventive interventions and biomarkers that can 
both identify persons at the earliest stages of lung cancer development 
and monitor the efﬁcacy of interventions.
The silencing of genes through promoter hypermethylation is now rec-
ognized as a major and causal epigenetic event that occurs during lung 
cancer initiation and progression. Genes silenced by methylation are in-
volved in all aspects of normal cellular function that include control of 
cell proliferation, differentiation, and death. The involvement of gene 
methylation in carcinogenesis has led to studies focused on establishing 
the utility of methylation as a biomarker in screening for cancer risk, 
prevention, treatment, and prognosis. The development of the methyla-
tion-speciﬁc PCR (MSP) assay has facilitated these studies because it 
allows for the assay of methylation of speciﬁc genes in biological ﬂuids 
such as sputum where epithelial cells comprise only a fraction of the 
cellular content.
In a small proof-of-concept study, we detected p16 or MGMT gene 
promoter methylation in sputum up to 3 years prior to the diagnosis of 
SCC. The evaluation of cancer-free individuals who were at risk for 
lung cancer because of smoking and/or exposure to radon through ura-
nium mining revealed methylation of the p16 and MGMT genes in 15% 
and 25% of sputum samples, respectively. The most striking difference 
seen between lung cancer cases and controls was the detection of both 
methylated genes in 48% of sputum samples from cases but only in 3% 
of controls. These ﬁndings were the ﬁrst to suggest that aberrant gene 
methylation could be highly sensitive as molecular markers in popula-
tion-based screening for early detection of lung cancer.
The well-documented ﬁeld cancerization seen in lungs of smokers 
stemming from exposure of the entire respiratory tract to inhaled 
carcinogens within cigarette smoke presents an obstacle to the early 
detection of lung cancer. The generation of multiple, independently 
initiated pre-malignant lesions throughout the lungs of people with a 
long history of smoking likely accounts for detecting methylation of 
genes such as p16 that is inactivated in the earliest stages of pre-inva-
sive disease. We hypothesized that the use of promoter methylation as 
a biomarker for early detection of lung cancer would require a panel 
of genes whose presence in sputum confer a high enough sensitivity 
and speciﬁcity for distinguishing very advanced dysplasia or early lung 
cancer from the large “at risk” population. This hypothesis was tested 
in Speciﬁc Aim 1 of this project by conducting a nested case-con-
trol study of incident lung cancer cases from an extremely high-risk 
cohort (developed through the Colorado Lung SPORE) for evaluating 
promoter methylation of 14 genes in sputum. Controls (n=92) were 
cohort members matched to cases (n=98) by gender, age, and month of 
enrollment. The comparison of proximal sputum collected within 18 
months to > 18 months prior to diagnosis showed that the prevalence 
for methylation of gene promoters increased as the time to lung cancer 
diagnosis decreased. Six of 14 genes were associated with a > 50% 
increased lung cancer risk. The concomitant methylation of three or 
more of these six genes was associated with a 6.5-fold increased risk 
and a sensitivity and speciﬁcity of 64%. These studies have now been 
extended to evaluate new cases and controls as well as 20 additional 
candidate genes. These results will be presented. In addition, studies are 
ongoing to assess methylation of a gene panel in sputum obtained from 
the prevalent Stage I lung cancer case that is generally asymptomatic 
